Aclaris Therapeutics, Inc. (ACRS)
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade
The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.13 per share a year ago.
3 Penny Stocks Under $5 Backed by Real Revenue Growth
Investing in penny stocks requires significant conviction. Many of the companies in this group are purely “story stocks.
Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.12 per share a year ago.
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.1 per share a year ago.
Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript
Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript
What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now?
Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.13 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.15 per share a year ago.
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy?
Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.24 per share a year ago.
